thalidomide has been researched along with Weight Loss in 13 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 6.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| "Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3',5'-monophosphate, resulting in increased intracellular cyclic adenosine 3',5'-monophosphate levels in phosphodiesterase 4-expressing cells." | 6.58 | Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. ( Puig, L; Torres, T, 2018) |
| "Treatment with apremilast was well tolerated, with generally mild gastrointestinal complaints, which occurred early in the course of the treatment and resolved over time, and there was no requirement for laboratory test monitoring." | 6.52 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. ( Gooderham, M; Papp, K, 2015) |
| "During the 24 weeks of treatment, diarrhea was observed in four patients, and diarrhea and nausea were observed in one patient." | 5.56 | Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. ( Sugai, S; Taguchi, R; Takamura, S; Teraki, Y, 2020) |
| "We conducted a prospective, open-label study (Immune Metabolic Associations in Psoriatic Arthritis) of adults receiving apremilast 30 mg as part of routine care for PsA and/or psoriasis." | 4.12 | Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study. ( Brooksbank, K; Brown, R; Cathcart, S; Ferguson, LD; Gao, X; Harvie, J; McInnes, IB; Paterson, C; Radjenovic, A; Rimmer, D; Sattar, N; Semple, G; Siebert, S; Welsh, P, 2022) |
| "Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin) (CPT-11)-based chemotherapy." | 3.73 | A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. ( Bian, JS; Chan, E; Duan, W; Hu, ZP; Huang, M; Li, X; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ, 2006) |
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 2.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| " Thalidomide, at the dosage used in this study, had no effect on peripheral CD4+ T cells nor on HIV viral burden in PBMC." | 2.68 | Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. ( Arroyo-Figueroa, H; Calva, JJ; Martínez del Cerro, V; Pasquetti, A; Reyes-Terán, G; Ruiz-Palacios, GM; Sierra-Madero, JG, 1996) |
| "Apremilast is an oral, small-molecule phosphodiesterase 4 inhibitor that works intracellularly by blocking the degradation of cyclic adenosine 3',5'-monophosphate, resulting in increased intracellular cyclic adenosine 3',5'-monophosphate levels in phosphodiesterase 4-expressing cells." | 2.58 | Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. ( Puig, L; Torres, T, 2018) |
| "Treatment with apremilast was well tolerated, with generally mild gastrointestinal complaints, which occurred early in the course of the treatment and resolved over time, and there was no requirement for laboratory test monitoring." | 2.52 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. ( Gooderham, M; Papp, K, 2015) |
| "During the 24 weeks of treatment, diarrhea was observed in four patients, and diarrhea and nausea were observed in one patient." | 1.56 | Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. ( Sugai, S; Taguchi, R; Takamura, S; Teraki, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Takamura, S | 1 |
| Sugai, S | 1 |
| Taguchi, R | 1 |
| Teraki, Y | 1 |
| Ferguson, LD | 1 |
| Cathcart, S | 1 |
| Rimmer, D | 1 |
| Semple, G | 1 |
| Brooksbank, K | 1 |
| Paterson, C | 1 |
| Brown, R | 1 |
| Harvie, J | 1 |
| Gao, X | 1 |
| Radjenovic, A | 1 |
| Welsh, P | 1 |
| McInnes, IB | 1 |
| Sattar, N | 1 |
| Siebert, S | 1 |
| Torres, T | 1 |
| Puig, L | 1 |
| Ighani, A | 1 |
| Georgakopoulos, JR | 1 |
| Shear, NH | 1 |
| Walsh, S | 1 |
| Yeung, J | 1 |
| Gooderham, M | 1 |
| Papp, K | 1 |
| Hackshaw, A | 1 |
| Woolard, S | 1 |
| Khan, ZH | 1 |
| Simpson, EJ | 1 |
| Cole, AT | 1 |
| Holt, M | 1 |
| MacDonald, I | 1 |
| Pye, D | 1 |
| Austin, A | 1 |
| Freeman, JG | 1 |
| Yang, XX | 1 |
| Hu, ZP | 1 |
| Xu, AL | 1 |
| Duan, W | 1 |
| Zhu, YZ | 1 |
| Huang, M | 1 |
| Sheu, FS | 1 |
| Zhang, Q | 1 |
| Bian, JS | 1 |
| Chan, E | 1 |
| Li, X | 1 |
| Wang, JC | 1 |
| Zhou, SF | 1 |
| Weinroth, SE | 1 |
| Parenti, DM | 1 |
| Simon, GL | 1 |
| Reyes-Terán, G | 1 |
| Sierra-Madero, JG | 1 |
| Martínez del Cerro, V | 1 |
| Arroyo-Figueroa, H | 1 |
| Pasquetti, A | 1 |
| Calva, JJ | 1 |
| Ruiz-Palacios, GM | 1 |
| Surawicz, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients (MEAS Study)[NCT04645420] | 19 participants (Actual) | Interventional | 2020-11-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Weight Loss
| Article | Year |
|---|---|
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Humans; Phosph | 2018 |
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Topics: Clinical Trials, Phase II as Topic; Depression; Drug Interactions; Humans; Phosphodiesterase 4 Inhib | 2015 |
Wasting syndrome in HIV/AIDS patients. A guide to prevention and management.
Topics: Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; HIV Wasting Syndrome; Human Growth Hormo | 2001 |
Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches.
Topics: Acetylcysteine; Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Body Comp | 1995 |
2 trials available for thalidomide and Weight Loss
| Article | Year |
|---|---|
Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.
Topics: Aged; Aged, 80 and over; Basal Metabolism; Body Composition; Body Mass Index; Cachexia; Energy Intak | 2003 |
Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; CD4 Lymphocyte Count; Cells, Cultured; Double-Blind Method; Female; Follow-Up Studies; HIV In | 1996 |
7 other studies available for thalidomide and Weight Loss
| Article | Year |
|---|---|
Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Dermatologic Agents; Diar | 2020 |
Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
Topics: Adult; Arthritis, Psoriatic; Body Fat Distribution; Cardiometabolic Risk Factors; Female; Humans; Ma | 2022 |
Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Headache; Humans; Long-Term Care; | 2019 |
Small studies: strengths and limitations.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Diet Therapy; Hum | 2008 |
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2006 |
Thalidomide for AIDS diarrhea?
Topics: AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Diarrhea; Humans; Microsporida | 1997 |
Weight loss update.
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Female; Growth Hormone; HIV Infections; | 1996 |